Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women. (February 2014)

• Record Type: Journal Article
• Authors: Rantell, Angie; Cardozo, Linda; Srikrishna, Sushma
• Is Part Of: Expert opinion on pharmacotherapy. Volume 15:Number 3(2014)
• Page Start: 385
• Page End: 393
• Publication Date: 2014-02
• Subjects: Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1517/14656566.2014.875158
• Languages: English
• ISSNs: 1465-6566

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> Urinary incontinence (UI) is a prevalent condition among women of all ages. It can have a significant negative impact on women's quality of life causing not only physical but also psychological distress.</p> <p> <bold> <italic>Areas covered:</italic> </bold> This article aims to provide a review of the pharmacology, efficacy, safety and tolerability of fesoterodine fumarate (the newest anticholinergic launched in the UK) and the oxybutynin vaginal ring (the newest route of drug delivery in development) in the treatment of urgency UI.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> Fesoterodine is now a well-established treatment option; however, as with all oral anticholinergic agents its use is hindered by side effects. The efficacy of the oxybutynin ring has only been demonstrated in small studies. Larger clinical trials assessing the efficacy, tolerability and acceptability are required before appropriate recommendations can be made.</p> </abstract>